Venetoclax Combos Improve Progression-Free Survival in CLL

Venetoclax/obinutuzumab as well as a triple combo with ibrutinib demonstrated better PFS in fit patients with CLL vs chemo, but higher rates of serious adverse events with ibrutinib remain a concern.
Medscape Medical News

Leave a Reply

Your email address will not be published. Required fields are marked *